Skip to Content
Merck
  • Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H.

Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H.

European journal of medicinal chemistry (2017-10-17)
Jayakanth Kankanala, Karen A Kirby, Andrew D Huber, Mary C Casey, Daniel J Wilson, Stefan G Sarafianos, Zhengqiang Wang
ABSTRACT

Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) is the only HIV enzymatic function not targeted by current antiviral drugs. Although various chemotypes have been reported to inhibit HIV RNase H, few have shown significant antiviral activities. We report herein the design, synthesis and biological evaluation of a novel N-hydroxy thienopyrimidine-2,3-dione chemotype (11) which potently and selectively inhibited RNase H with considerable potency against HIV-1 in cell culture. Current structure-activity-relationship (SAR) identified analogue 11d as a nanomolar inhibitor of RNase H (IC

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2,3-Dihydroxypyridine, 95%